Loading candles…
Marksans Pharma operates in the pharmaceutical industry focusing on the formulation of pharmaceutical products, primarily generic drugs. The company encompasses activities across the pharmaceutical value chain including research and development, manufacturing, and global marketing. It serves markets in the United Kingdom, United States, Australia, and Europe. Marksans Pharma's business segments include Research and Development (R&D), Manufacturing, Global Marketing, the Over-the-Counter (OTC) segment, and the Prescription (Rx) market. The OTC pharmaceutical segment accounts for the majority of the company's revenue. No information on founders, key management, incorporation details, subsidiaries, or stock listings is provided.
| Type | Details | Date |
|---|---|---|
| Audited Results - FY26 | To consider and approve Audited Standalone and Consolidated Financial Results and to consider recommendation of dividend if any, for the Financial Year ended… | 26 May 2026 |
| Results - Q3-FY25 | To consider and approve the financial results for the quarter ended December 31, 2025 | 5 Feb 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended September 30, 2025 | 13 Nov 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended Jun 30, 2025 | 12 Aug 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended March 31, 2025 and dividend | 19 May 2025 |
Besseggen InfoTech LLP is a SEBI-registered stock broker (Reg. No. INZ000213450), member of NSE (90155 (Cash & F&O)) and BSE (6722 (Cash & F&O)). Investment in securities market are subject to market risks; read all related documents carefully before investing.